Overview

S-Nitrosylation Therapy of COVID-19

Status:
Active, not recruiting

Trial end date:
2022-04-30

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to provide expanded access of S-nitrosylation therapy for the treatment of severe acute respiratory syndrome coronavirus (SARS-CoV2) infection.

Phase:

Early Phase 1

Details

Lead Sponsor:

Robert Schilz

Collaborator:

Case Western Reserve University